Amundi Pioneer Asset Management Inc. Purchases Shares of 38,335 Inogen, Inc (INGN)
Amundi Pioneer Asset Management Inc. purchased a new position in shares of Inogen, Inc (NASDAQ:INGN) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 38,335 shares of the medical technology company’s stock, valued at approximately $3,646,000. Amundi Pioneer Asset Management Inc. owned approximately 0.18% of Inogen as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Piedmont Investment Advisors LLC acquired a new position in Inogen during the 2nd quarter worth approximately $336,000. Parametric Portfolio Associates LLC grew its holdings in Inogen by 63.6% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 45,969 shares of the medical technology company’s stock worth $4,386,000 after acquiring an additional 17,867 shares in the last quarter. Morgan Stanley grew its holdings in Inogen by 74.6% during the 1st quarter. Morgan Stanley now owns 86,859 shares of the medical technology company’s stock worth $6,737,000 after acquiring an additional 37,099 shares in the last quarter. Vanguard Group Inc. grew its holdings in Inogen by 24.9% during the 2nd quarter. Vanguard Group Inc. now owns 1,515,342 shares of the medical technology company’s stock worth $144,594,000 after acquiring an additional 301,737 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its holdings in Inogen by 4.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 293,070 shares of the medical technology company’s stock worth $27,964,000 after acquiring an additional 13,160 shares in the last quarter.
Several research analysts have commented on the stock. BidaskClub upgraded shares of Inogen from a “buy” rating to a “strong-buy” rating in a report on Tuesday, August 8th. Zacks Investment Research downgraded shares of Inogen from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 8th. Needham & Company LLC boosted their price objective on shares of Inogen from $108.00 to $125.00 and gave the stock a “strong-buy” rating in a research report on Wednesday, November 8th. Leerink Swann restated an “outperform” rating and set a $120.00 price objective (up previously from $115.00) on shares of Inogen in a research report on Wednesday, November 8th. Finally, Piper Jaffray Companies restated a “hold” rating and set a $90.00 price objective on shares of Inogen in a research report on Tuesday, September 12th. Three equities research analysts have rated the stock with a hold rating, three have assigned a buy rating and two have issued a strong buy rating to the company. The company has an average rating of “Buy” and an average target price of $103.14.
Shares of Inogen, Inc (NASDAQ INGN) opened at $122.99 on Friday. Inogen, Inc has a 12-month low of $60.02 and a 12-month high of $130.05. The company has a market cap of $2,686.85, a price-to-earnings ratio of 104.67, a P/E/G ratio of 5.41 and a beta of 1.12.
Inogen (NASDAQ:INGN) last released its quarterly earnings results on Tuesday, November 7th. The medical technology company reported $0.33 EPS for the quarter, beating the consensus estimate of $0.29 by $0.04. Inogen had a net margin of 11.36% and a return on equity of 13.37%. The firm had revenue of $69.00 million during the quarter, compared to the consensus estimate of $63.55 million. During the same quarter in the prior year, the firm earned $0.25 EPS. Inogen’s revenue for the quarter was up 26.8% on a year-over-year basis. analysts expect that Inogen, Inc will post 1.19 earnings per share for the current year.
In other Inogen news, EVP Matt Scribner sold 2,500 shares of the company’s stock in a transaction on Thursday, October 12th. The shares were sold at an average price of $93.88, for a total transaction of $234,700.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Raymond Huggenberger sold 14,000 shares of the company’s stock in a transaction on Friday, September 15th. The stock was sold at an average price of $102.30, for a total transaction of $1,432,200.00. Following the transaction, the director now owns 7,808 shares of the company’s stock, valued at approximately $798,758.40. The disclosure for this sale can be found here. In the last quarter, insiders sold 88,000 shares of company stock valued at $9,277,330. 5.31% of the stock is owned by insiders.
Inogen Company Profile
Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.
Receive News & Ratings for Inogen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen Inc and related companies with MarketBeat.com's FREE daily email newsletter.